Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGc-043 in EBV-positive Advanced Malignant Tumors
NCT05714748Phase 1Active, not recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- Vaccine mRNA, mRNA Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WGc-043 in malignant neoplasm, sponsored by West China Hospital of Sichuan University. Primary endpoints: Adverse events up to 12 months, Objective response rate up to 12 months and 2 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
WGc-043
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT05714748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05714748.